Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roivant Sciences Ltd (NQ: ROIV ) 10.52 -0.05 (-0.52%) Streaming Delayed Price Updated: 1:27 PM EDT, Jun 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,414,550 Open 10.57 Bid (Size) 10.51 (21) Ask (Size) 10.52 (33) Prev. Close 10.57 Today's Range 10.44 - 10.75 52wk Range 8.245 - 13.24 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Evaluating Roivant Sciences: Insights From 6 Financial Analysts June 18, 2024 Via Benzinga The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts May 31, 2024 Via Benzinga Performance YTD -7.36% -7.36% 1 Month -2.91% -2.91% 3 Month -0.24% -0.24% 6 Month -7.52% -7.52% 1 Year +4.42% +4.42% More News Read More ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024 May 30, 2024 Via InvestorPlace Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update May 30, 2024 From Roivant Sciences Via GlobeNewswire Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On? May 22, 2024 Via Benzinga Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know April 22, 2024 Via Benzinga Where Roivant Sciences Stands With Analysts March 25, 2024 Via Benzinga The Analyst Landscape: 4 Takes On Roivant Sciences February 14, 2024 Via Benzinga Roivant Sciences Earnings Preview February 12, 2024 Via Benzinga Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 May 16, 2024 From Roivant Sciences Via GlobeNewswire Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare May 07, 2024 Via InvestorPlace 3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 May 01, 2024 Via InvestorPlace Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study April 02, 2024 Via Benzinga Assessing Roivant Sciences: Insights From 5 Financial Analysts January 02, 2024 Via Benzinga Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study April 02, 2024 Via Investor's Business Daily Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million April 02, 2024 From Roivant Sciences Via GlobeNewswire 10 Health Care Stocks Whale Activity In Today's Session March 29, 2024 Via Benzinga Solar Stocks Rally, Led By Sunrun, SolarEdge, Enphase March 27, 2024 Via Investor's Business Daily 5 Value Stocks In The Healthcare Sector February 19, 2024 Via Benzinga Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update February 13, 2024 From Roivant Sciences Via GlobeNewswire Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 January 30, 2024 From Roivant Sciences Via GlobeNewswire Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space January 12, 2024 Via Investor's Business Daily Earnings Scheduled For February 13, 2024 February 13, 2024 Via Benzinga Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations January 10, 2024 Via Benzinga Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50% December 21, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
